{"id":"d-ribose-powder","_chembl":{"chemblId":"CHEMBL1159662","moleculeType":"Small molecule","molecularWeight":"150.13"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"D-Ribose is a pentose sugar that serves as a building block for adenosine triphosphate (ATP), the primary energy currency of cells. By providing substrate for the pentose phosphate pathway and nucleotide synthesis, it may help restore depleted ATP levels in tissues with high energy demands.","oneSentence":"D-Ribose serves as a substrate for ATP synthesis, potentially supporting cellular energy metabolism and recovery."},"_scrapedAt":"2026-03-28T03:30:41.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123817,"model":"claude-sonnet-4-5-20250929"},"description":"D-Ribose is a naturally occurring five-carbon sugar that plays a role in cellular energy production through ATP synthesis. It is being investigated by RiboCor, Inc. as a potential therapeutic agent, currently in Phase 2 clinical development, though specific indications and molecular targets have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Unknown indication under investigation","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03308942","phase":"PHASE2","title":"Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-09-29","conditions":"Neoplasms","enrollment":53},{"nctId":"NCT03182673","phase":"PHASE1","title":"The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-24","conditions":"Solid Tumor","enrollment":31},{"nctId":"NCT03133793","phase":"PHASE2","title":"CoQ10 and D-ribose in Patients With Diastolic Heart Failure","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-05","conditions":"Heart Failure, Diastolic","enrollment":216},{"nctId":"NCT04545190","phase":"NA","title":"RibOSE - Glucose and Resistance Exercise Training","status":"COMPLETED","sponsor":"Inland Norway University of Applied Sciences","startDate":"2020-09-01","conditions":"Healthy","enrollment":16},{"nctId":"NCT03411369","phase":"NA","title":"Creatine, D-Ribose, B1 Vitamin, and B6 Vitamin in Ischemic Heart Disease","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2016-06-01","conditions":"Ischemic Heart Disease","enrollment":55},{"nctId":"NCT01858480","phase":"PHASE2","title":"Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure","status":"WITHDRAWN","sponsor":"RiboCor, Inc.","startDate":"2013-07","conditions":"Congestive Heart Failure","enrollment":""},{"nctId":"NCT01315210","phase":"PHASE2","title":"D-Ribose for Fatigue in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"RiboCor, Inc.","startDate":"2011-05","conditions":"Fibromyalgia","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ribose"],"phase":"phase_2","status":"active","brandName":"D-Ribose Powder","genericName":"D-Ribose Powder","companyName":"RiboCor, Inc.","companyId":"ribocor-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}